Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF CNMDC

FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 25 October 2019 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. ("CNMDC"), a subsidiary of the Company for the nine months ended 30 September 2019 issued on the websites of China Money and Shanghai Clearing House by CNMDC.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the nine months ended 30 September 2019 as set out in this Announcement.

PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan

Currency: RMB

Changes of this period

Current period Same period of last year over same period of last year

Revenue

Operating profit

Total comprehensive income attributable to owners of the parent company

Net cash flow arising from operating activities

Total assets

Total equity attributable to owners (or shareholders) of the parent company

29,934,619,653.22

1,098,583,509.73

471,956,024.99

-2,175,883,126.95

At the end of the reporting period

29,761,951,380.95

4,480,712,841.99

21,904,786,847.71 36.66%

788,574,346.26 39.31%

349,996,672.13 34.85%

-2,367,835,691.78-8.11%

Changes of At the beginning of the this period-

reporting period end over the beginning of

this period

21,868,609,223.01 36.09%

4,106,634,043.32 9.11%

By order of the Board of

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC

25 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Dai Kun; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

  • The Company is registered as a non-Hong Kong company under the Hong Kong
    Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

Attachments

  • Original document
  • Permalink

Disclaimer

Sinopharm Group Co. Ltd. published this content on 25 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 October 2019 15:50:17 UTC